Homepage Top Section2

The phase II Eagle trial is a randomized, open-label and multi-centre trial designed to assess Imfinzi monotherapy and Imfinzi in combination with anti-CTLA4 antibody tremelimumab against SoC chemotherapy

UCB will build a new £150mto £200m research and development facility as part of the total investment over the next five years. The transition to the facility will

The phase 3 MAIA study showed that the daratumumab, in combination with lenalidomide and dexamethasone (Rd), has reduced the risk of disease progression or death in patients with

DeepMind further claimed that its AI-driven system, AlphaFold, is capable of generating 3D models of proteins that are highly accurate and potentially capable of solving one of the

RXC006 is being developed as an orally administered and first-in-class treatment for the orphan disease idiopathic pulmonary fibrosis (IPF), which is a chronic lung condition. RXC006, which is

According to Cyxone, T20K during the preclinical program has been shown to be safe for people to ingest. The Swedish clinical biotech company, which has concluded the preclinical

Janssen Research & Development is undertaking the study. Vedanta Biosciences had granted the licensing rights of VE202 in 2015 to Janssen Biotech. The microbiome-derived product candidate is being

The trial has not achieved its primary endpoint of OS with Opdivo (nivolumab) 1mg/kg in combination with Yervoy (ipilimumab) 3mg/kg against placebo as a maintenance therapy for patients

The approval of Pelmegis follows the recommendation of the Medicinal Products for Human Use (CHMP), which was based on regulatory submission of significant biosimilarity data from analytical, biofunctional